Resource Logo
AIDS Treatment News

Peptide T: Negative Trial Result




 

AIDS TREATMENT NEWS #234, November 3, 1995

A government study of 215 volunteers with AIDS-related cognitive impairment found no proof that peptide T was helpful for treating this condition.

The volunteers were randomly assigned to receive either peptide T (intranasally, up to six mg/day) or placebo for six months; for the next six months, everyone was given peptide T, and they could continue the medication beyond one year if they wanted. Cognitive impairment (which includes difficulties with memory, attention, language, problem solving, spatial ability, and visual-motor coordination) was measured by standard neuropsychological tests. The treatment group showed no statistically significant improvement compared to the control group.

The study also found no toxicity from peptide T.

Recruiting for this study began in March 1991. It took a long time to find volunteers -- probably because AIDS-related cognitive impairment is less common than had been expected, and because it can often be treated effectively with AZT.

This clinical trial was conducted by the U.S. National Institute of Mental Health, with additional funding from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).



 


Copyright © 1995 -AIDS Treatment News, Publisher. All rights reserved to AIDS Treatment News (ATN), Email AIDS Treatment News .

Information in this article was accurate in November 3, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.